Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Nov;37(11):2470–2473. doi: 10.1128/aac.37.11.2470

Bactericidal activity of the fluoroquinolone WIN 57273 against high-level gentamicin-resistant Enterococcus faecalis.

G A Noskin 1, P Mehl 1, J R Warren 1
PMCID: PMC192411  PMID: 8285636

Abstract

The fluoroquinolone WIN 57273 showed identical bactericidal activities (MBC for 90% of the strains = 0.25 micrograms/ml) for bacteremic strains of Enterococcus faecalis with and without high-level gentamicin resistance. WIN 57273 was bactericidal in time-kill measurements with highly gentamicin-resistant, ciprofloxacin-susceptible strains of E. faecalis. However, WIN 57273 was indifferent with penicillin for gentamicin-resistant E. faecalis and was not bactericidal for ciprofloxacin-resistant E. faecalis.

Full text

PDF
2470

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Eliopoulos G. M., Klimm K., Eliopoulos C. T., Ferraro M. J., Moellering R. C., Jr In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother. 1993 Feb;37(2):366–370. doi: 10.1128/aac.37.2.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fernandez-Guerrero M., Rouse M. S., Henry N. K., Geraci J. E., Wilson W. R. In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis. Antimicrob Agents Chemother. 1987 Mar;31(3):430–433. doi: 10.1128/aac.31.3.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fuchs P. C., Barry A. L., Pfaller M. A., Allen S. D., Gerlach E. H. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother. 1991 Apr;35(4):764–766. doi: 10.1128/aac.35.4.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Jones R. N., Barry A. L. In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother. 1990 Feb;34(2):306–313. doi: 10.1128/aac.34.2.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kaatz G. W., Seo S. M. WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens. Antimicrob Agents Chemother. 1990 Jul;34(7):1376–1380. doi: 10.1128/aac.34.7.1376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Miranda A. G., Wanger A. R., Singh K. V., Murray B. E. Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci. Antimicrob Agents Chemother. 1992 Jun;36(6):1325–1328. doi: 10.1128/aac.36.6.1325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Moody J. A., Peterson L. R., Gerding D. N. In vitro activity of ciprofloxacin combined with azlocillin. Antimicrob Agents Chemother. 1985 Dec;28(6):849–850. doi: 10.1128/aac.28.6.849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Neu H. C. Synergy of fluoroquinolones with other antimicrobial agents. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S1025–S1035. doi: 10.1093/clinids/11.supplement_5.s1025. [DOI] [PubMed] [Google Scholar]
  9. Noskin G. A., Till M., Patterson B. K., Clarke J. T., Warren J. R. High-level gentamicin resistance in Enterococcus faecalis bacteremia. J Infect Dis. 1991 Dec;164(6):1212–1215. doi: 10.1093/infdis/164.6.1212. [DOI] [PubMed] [Google Scholar]
  10. Sahm D. F., Torres C. High-content aminoglycoside disks for determining aminoglycoside-penicillin synergy against Enterococcus faecalis. J Clin Microbiol. 1988 Feb;26(2):257–260. doi: 10.1128/jcm.26.2.257-260.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Sato K., Hoshino K., Tanaka M., Hayakawa I., Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother. 1992 Jul;36(7):1491–1498. doi: 10.1128/aac.36.7.1491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Schaberg D. R., Dillon W. I., Terpenning M. S., Robinson K. A., Bradley S. F., Kauffman C. A. Increasing resistance of enterococci to ciprofloxacin. Antimicrob Agents Chemother. 1992 Nov;36(11):2533–2535. doi: 10.1128/aac.36.11.2533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sedlock D. M., Dobson R. A., Deuel D. M., Lesher G. Y., Rake J. B. In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria. Antimicrob Agents Chemother. 1990 Apr;34(4):568–575. doi: 10.1128/aac.34.4.568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Spiegel C. A., Huycke M. Endocarditis due to streptomycin-susceptible Enterococcus faecalis with high-level gentamicin resistance. Arch Intern Med. 1989 Aug;149(8):1873–1875. [PubMed] [Google Scholar]
  15. Wakebe H., Mitsuhashi S. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria. Antimicrob Agents Chemother. 1992 Oct;36(10):2185–2191. doi: 10.1128/aac.36.10.2185. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES